CHOROIDAL NEOVASCULARIZATION SECONDARY TO PHOTODYNAMIC THERAPY FOR CENTRAL SEROUS CHORIORETINOPATHY: Incidence, Risk Factors, and Clinical Outcomes

Retina. 2021 Aug 1;41(8):1762-1770. doi: 10.1097/IAE.0000000000003067.

Abstract

Purpose: To investigate the incidence, risk factors, and clinical outcomes of complicated choroidal neovascularization (CNV) after reduced-fluence photodynamic therapy (PDT) for central serous chorioretinopathy.

Methods: This is a retrospective consecutive interventional study including 559 eyes from 520 patients treated by reduced-fluence PDT for central serous chorioretinopathy. The incidence of complicated CNV within 3 months after PDT was calculated. Baseline demographics and ocular findings were investigated to identify risk factors. The clinical course of complicated CNV was analyzed.

Results: Seven cases experienced development of active CNV after PDT within 3 months with a median interval of 4 weeks (range, 2-12 weeks). The incidence was estimated as 1.25% (95% CI, 0.55-2.62%). Complicated CNV developed in 6 among 138 eyes (4.35%) with flat irregular pigment epithelial detachment and in 1 among 421 eyes (0.24%) without flat irregular pigment epithelial detachment (P < 0.001, Fisher's exact test). The median best-corrected visual acuity recovered from 20/100 at the time of CNV development to 20/20 after anti-vascular endothelial growth factor injections (median, 3 times).

Conclusion: In approximately 1%, reduced-fluence PDT for central serous chorioretinopathy may be complicated by CNV, which can be well controlled with anti-vascular endothelial growth factor injection. Flat irregular pigment epithelial detachment increases the risk of secondary CNV following PDT.

MeSH terms

  • Central Serous Chorioretinopathy / drug therapy
  • Choroidal Neovascularization / diagnosis
  • Choroidal Neovascularization / epidemiology*
  • Choroidal Neovascularization / etiology
  • Female
  • Fluorescein Angiography / methods
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Photochemotherapy / adverse effects*
  • Photosensitizing Agents / therapeutic use
  • Republic of Korea / epidemiology
  • Retinal Pigment Epithelium / diagnostic imaging*
  • Retrospective Studies
  • Risk Factors
  • Tomography, Optical Coherence / methods
  • Verteporfin / therapeutic use*
  • Visual Acuity*

Substances

  • Photosensitizing Agents
  • Verteporfin